KaydedilenlerDerginizi ekleyin

Dergiler / Yeni Tıp Dergisi / 2013 / Cilt: 30 - Sayı: 2

Decreased hepcidin-25 level as a predictor of poor prognosis in acute coronary syndrome patients

Akut koroner sendromlu hastalarda kötü prognoz göstergesi olarak azalmıştır Hepsidin-25 Düzeyi

Tolga ÇİMEN
Ekrem YETER
Mehmet DOĞAN
Murat AKÇAY
HÜSEYİN AYHAN
Telat KELEŞ
Tahir DURMAZ
Nihal Akar BAYRAM
Engin BOZKURT
Sayfa
115–120
DOI
—
🏛️Bu makalenin bibliyografik verileri ve tam metin bağlantısı DergiPark üzerinden sağlanmıştır.
DergiPark Kaydı ↗
✨

Yapay Zeka Hızlı Bakış & Çıkarımlar

AI Insight
⚡ TL;DR(1 Cümlede Hızlı Çıkarım)

Reduced serum hepcidin-25 levels might predict poor outcome in patients with ACS.

📌 3 Maddede Bu Makale

🎯
Amaç & Hipotez:Background: The peptide hormone hepcidin-25 is known as a type-II acute phase protein in patients with chronic inflammatory conditions and it has a central role in iron homeostasis as well as in anemia, inflammation and hypoxia.
📊
Temel Bulgular & Veri:Herein, we evaluated whether hepcidin-25 level has a prognostic role in patients with acute coronary syndromes (ACS).
💡
Sonuç & Katkı:Reduced serum hepcidin-25 levels might predict poor outcome in patients with ACS.
🔬Tür:Araştırma Makalesi
📍Kapsam:Genişletilmiş Akademik Örneklem
⚙️Değişkenler:Alan Parametreleri

Abstract

Background: The peptide hormone hepcidin-25 is known as a type-II acute phase protein in patients with chronic inflammatory conditions and it has a central role in iron homeostasis as well as in anemia, inflammation and hypoxia. Atherosclerosis is widely accepted as a chronic inflammatory disease. Herein, we evaluated whether hepcidin-25 level has a prognostic role in patients with acute coronary syndromes (ACS). Material and Method: Forty-eight patients with ACS admitted to the coronary care unit of our hospital were included in Group 1, 19 patients without any significant coronary artery disease were included in Group 2 and 20 healthy subjects as control were included in Group 3. Serum hepcidin-25 levels were measured with Hepcidin ELISA kits. Results: Patients with ACS were followed-up for up to 24 months after admission with regard to cardiac events including death, myocardial infarction and revascularisa- tion. There was no significant difference between the baseline biochemical and clinical characteristics of Group 1 and Group 2. Hepcidin-25 level was lower in Group 1 when compared with other Groups (192± 74 ng/mL, 296 ±104 ng/mL, 303.8±92.1, p<0.01). Hepcidin-25 level was found significantly lower in patients who developed a cardiac event compared to those who did not (140 ± 78 ng/ml vs 208±74 ng/ml, p<0.05) but ferritin and hsCRP were similar. Conclusions . Reduced serum hepcidin-25 levels might predict poor outcome in patients with ACS.

🔖

Bu Makaleye Atıf Yap

ÇİMEN, T., YETER, E., DOĞAN, M., AKÇAY, M., AYHAN, H., KELEŞ, T., DURMAZ, T., BAYRAM, N. A., BOZKURT, E. (2013). Decreased hepcidin-25 level as a predictor of poor prognosis in acute coronary syndrome patients. Yeni Tıp Dergisi, Cilt: 30 - Sayı: 2, 115–120. https://ajindex.com/articles/338205

📄 Tam Metin PDF Okuyucu

📄

PDF görüntüleyici hazırlanıyor...

Kaynakça (13)

  1. Ramakrishna G, Rooke TW, Cooper LT. Iron and peripheral arterial disease: revisiting the iron hypothesis in a different light. Vasc Med 2003;8(3):203-10
  2. Turoczi T, Jun L, Cordis G, Morris JE, Maulik N, Stevens RG, et al. HFE mutation and dietary iron content interact to increase ischemia/ reperfusion injury of the heart in mice. Circ Res 2003;92(11):1240-6
  3. Oudit GY, Trivieri MG, Khaper N, Husain T, Wilson GJ, Liu P, et al. Taurine supplementation reduces oxidative stress and improves cardiovascular function in an iron-overload murine model. Circulation 2004;109(15):1877-85
  4. Krause A, Neitz S, Mägert HJ, Schulz A, Forssmann WG, Schulz- Knappe P, et al. LEAP-1, a novel highly disulfide-bounded human peptide, exhibits antimicrobial activity. FEBS Lett 2000;480(2-3):147-50
  5. Park CH, Valore EV, Waring AJ, Ganz T. Hepcidin, a urinary antimicrobial peptide synthesized in the liver. J Biol Chem 2001;276(11): 7806-10
  6. Nicolas G, Chauvet C, Viatte L, Danan JL, Bigard X, Devaux I, et al. The gene encoding the iron regulatory peptide hepcidin is regulated by anemia, hypoxia, and inflammation. J Clin Invest 2002;110(7):1037-44
  7. Pigeon C, Ilyin G, Courselaud B, Leroyer P, Turlin B, Brissot P, et al. A new mouse liver-specific gene, encoding a protein homologous to human antimicrobial peptide hepcidin, is overexpressed during iron overload. J Biol Chem 2001;276(11):7811-9
  8. Nemeth E, Tuttle MS, Powelson J, Vaughn MB, Donovan A, Ward DM, et al. Hepcidin regulates cellular iron efflux by binding to ferroportin and inducing its internalization. Science 2004;306(5704):2090-3
  9. Lee P, Peng H, Gelbart T, Beutler E. The IL-6- and lipopolysaccharide-induced transcription of hepcidin in HFE-, transferrin receptor 2-, and beta 2-microglobulin-deficient hepatocytes. Proc Natl Acad Sci U S A 2004;101(25):9263-5
  10. Nemeth E, Valore EV, Territo M, Schiller G, Lichtenstein A, Ganz T. Hepcidin, a putative mediator of anemia of inflammation, is a type II acute- phase protein. Blood 2003;101(7):2461-3
  11. Ganz T. Hepcidin, a key regulator of iron metabolism and mediator of anemia of inflammation. Blood 2003;102(3):783-8
  12. Suzuki H, Toba K, Kato K, Ozawa T, Tomosugi N, Higuchi M, et al. Serum hepcidin-20 is elevated during the acute phase of myocardial infarction. Tohoku J Exp Med 2009;218(2):93-8
  13. Antman EM, Anbe DT, Armstrong PW, Bates ER, Green LA, Hand M, et al. ACC/AHA guidelines for the management of patients with ST- elevation myocardial infarcti